The award criteria for the evaluation of the contract to supply Human papillovirus (HPV) vaccine is set out as follows. These do not include criteria regarding experience in other countries.
Criteria Points Quality of protection against cervical cancers caused by HPV strains 16/18 Maximum (Max) of 5,000 Duration of protection against cervical cancers caused by HPV strains 16/18 for more than 10 years duration Max of 3,000 Quality of protection against anogenital warts caused by HPV Strains 6/11 Max of 1,300 Duration of protection against anogenital warts caused by HPV Strains 6/11 for more than 10 years duration Max of 500 Quality of protection against HPV strains not included in the vaccine formulation Max of 1000 Other evidence of additional clinical benefits Max of 500 Effective Price per dose excluding VAT Commercially confidential Supply of the vaccine as single pre-filled syringe pack presentation Max of 10 Quality of labelling, leaflets and presentation Max of 5 Shelf life Max of 120 Flexibility in the vaccine dosage schedule Max of 70 Offers that reduce the risk of wastage if the vaccine is subject to temperatures above 8°C (this include the provision of temperature indicators and evidence based guidance on the stability of the vaccines at higher storage temperatures and subsequent safe administration.) Max of 200 Closeness of proposed delivery schedule to Authority requirements Max of 200 Pallet configuration including a preference for the use of Euro pallets Max of 5 Impact of proposed amendments to the terms and conditions (-500). Offerors may lose up to 500 points Quality/Robustness of manufacturing contingency arrangements Max of 10 Quality/Robustness of the risk Management of storage and distribution Max of 10 Information provided relating to pack sizes, Cold Chain Delivery, Batch Numbering systems and production capacity Max of 5